Targretin

Phase 3

Ligand Pharmaceuticals Incorporated (LGND)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Alopecia Areata

QTTBbempikibart

View Full Landscape

Drug Information

Target Indication

Alopecia Areata

Clinical Trial

NCT00063076

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/29/2001

Targretin

Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

LGND

Ligand Pharmaceuticals Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

lasofoxifenePhase 3

Osteoporosis

MB07803Phase 2

Type 2 Diabetes Mellitus

MB07133Phase 2

Hepatocellular Carcinoma

bexarotenePhase 2

Breast Cancer

LGD-6972-5 mgPhase 2

Type 2 Diabetes Mellitus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts